Antibiotic resistance has become a major public health problem: there are 25,000 deaths each year due to antibiotic-resistant bacteria in Europe. Moreover, in the current therapeutic research programs, no antibiotics that can reach market within 8 to 10 years are in development.
Specializing in research and development of lytic bacteriophage for therapeutic and diagnostic applications, Pherecydes Pharma offers a realistic alternative to the therapeutic impasse faced by antibiotics. Antibiotic resistance is thus the primary target market of the Company. Therefore, Pherecydes Pharma intends to promote phage therapy as a credible alternative and complement to antibiotic therapy. With its unique expertise in the characterization and rapid isolation of phages, the Company has developed several large banks of bacteriophages, including the most important world collection of phages against E. coli. Our scientists also work on Pseudomonas and Staphylococcus. These three species alone amount to 50% of bacterial infections in industrialized countries. In addition, proof of concept tests conducted in animals have shown a complete lack of toxicity, full tolerance and a perfect 100% efficiency, which demonstrates the therapeutic potential of its products.
Pherecydes Pharma drug development pipeline
Two phage cocktails targeting, either the infections caused by E. coli (PP0121) or those induced by P. aeruginosa (PP1131), are being evaluated in humans (clinical Phase I / II). PP1231 aiming at respiratory infections caused by P. aeruginosa is currently being evaluated in animals. PP2351 againts infections caused by staphylococci is in final development into the lab before testing in various animal models.